Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Genesis Therapeutics inflammatory signaling pathway inhibitor
- Development stage
- Unknown
- Lead developer
- Genesis Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Genesis Therapeutics is developing a small molecule inhibitor targeting an undisclosed protein central to inflammatory signaling pathways for the treatment of autoimmune diseases. Discovered and optimized using the company's proprietary GEMS (Genesis Exploration of Molecular Space) AI platform—which combines deep learning with molecular simulations—the program aims to provide potent, oral treatment options for targets that have traditionally been addressed only by biologics. By inhibiting key signaling nodes in inflammatory pathways, the therapy is designed to reduce the underlying inflammation associated with various autoimmune disorders. The program is currently in the discovery phase and is part of Genesis's internal immunology and inflammation pipeline.
- Other names
- Novel immunology small molecule inhibitorGenesis Therapeutics autoimmune disease program
02
Targets
NF-κB
Beyond the preview
Go deeper on Genesis Therapeutics inflammatory signaling pathway inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genesis Therapeutics inflammatory signaling pathway inhibitor.